Kala Bio, Inc.
A biopharmaceutical company developing treatments for eye diseases, best known for EYSUVIS, an eye drop approved to treat inflammation and pain after eye surgery. The company, founded in 2009 as Kala Pharmaceuticals and renamed Kala Bio, also developed Inveltys for ocular inflammation. Its name was inspired by the medical journal of the American Academy of Ophthalmology, which in early years was called "Kala" — a nod to the field it serves.
Sold 3.83M
Granted 40.0K · Bought 9.29M
Bought 6.34M
Bought 755.1K
Bought 559.8K
Granted 40.0K · Bought 3.36M
Bought 2.96M
Bought 215.0K
Bought 430.0K
Granted 196.9K · Sold 38.5K
Granted 5.42M
Granted 615.0K · Sold 265.3K
Granted 195.9K · Sold 18.8K
Bought 310.6K · Sold 730.4K
Granted 40.0K
Granted 366.4K · Sold 34.8K
Granted 390.6K · Sold 87.6K
Granted 226.8K · Bought 10.0K · Sold 87.6K
Granted 218.2K · Sold 66.2K
Granted 68.9K
Granted 60.3K · Bought 5.0K
Granted 52.5K
Granted 10.4K
Granted 10.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kolchinsky Peter +3 co-filers10% owner · 6 transactions | — | 24.56Mas of May 2022 | — | — | 3.83M |
| Shah Rajeev M.Director · 6 transactions | — | 21.79Mas of Jun 2021 | 40.0K | 9.29M | — |
| Kolchinsky Peter +2 co-filersDirector, 10% owner · 1 transaction | — | 10.87Mas of Mar 2020 | — | 6.34M | — |
| Orbimed Advisors LLC +1 co-filer10% owner · 11 transactions | — | 9.78Mas of Feb 2018 | — | 755.1K | — |
| Isaly Samuel D +2 co-filers10% owner · 5 transactions | — | 7.20Mas of Jan 2018 | — | 559.8K | — |
| Grunberg GregoryDirector · 6 transactions | — | 5.45Mas of Jun 2021 | 40.0K | 3.36M | — |
| Kolchinsky Peter +2 co-filersDirector, 10% owner · 3 transactions | — | 4.54Mas of Oct 2018 | — | 2.96M | — |
| Enright Patrick G +3 co-filers10% owner · 2 transactions | — | 2.06Mas of Jul 2017 | — | 215.0K | — |
| Tepper Robert IDirector · 1 transaction | — | 1.62Mas of Jul 2017 | — | — | — |
| Hadley Harbor Master Investors (Cayman) L.P.10% owner · 2 transactions | — | 846.6Kas of Jul 2017 | — | — | — |
| Caxton Corp +2 co-filers10% owner · 4 transactions | — | 548.8Kas of Jul 2017 | — | 430.0K | — |
| Chen HongmingCHIEF SCIENTIFIC OFFICER · 12 transactions | — | 204.5Kas of Oct 2021 | 196.9K | — | 38.5K |
| Blumenkranz Mark S.Director · 13 transactions | — | 182.8Kas of Jun 2024 | 5.42M | — | — |
| Iwicki Mark TDirector · 22 transactions | — | 103.5K | 615.0K | — | 265.3K |
| Trachtenberg EricSEE REMARKS · 15 transactions | — | 69.3Kas of Jan 2024 | 195.9K | — | 18.8K |
| Baker Bros. Advisors LP +3 co-filersFormer 10% owner · 6 transactions | — | 46.5K | — | 310.6K | 730.4K |
| Paull Robert BradleyDirector · 6 transactions | — | 42.4Kas of Jun 2021 | 40.0K | — | — |
| Kharabi DariusCHIEF BUSINESS OFFICER · 15 transactions | — | 41.8K | 366.4K | — | 34.8K |
| Brazzell Romulus KSEE REMARKS · 26 transactions | — | 36.0K | 390.6K | — | 87.6K |
| Bazemore ToddDirector · 24 transactions | — | 35.9K | 226.8K | 10.0K | 87.6K |
| Reumuth MaryCHIEF FINANCIAL OFFICER · 26 transactions | — | 28.9K | 218.2K | — | 66.2K |
| Koven Andrew IDirector · 7 transactions | — | 17.0Kas of Jun 2025 | 68.9K | — | — |
| Rosen Howard BDirector · 10 transactions | — | 16.5Kas of Jun 2025 | 60.3K | 5.0K | — |
| Perry Gregory DDirector · 7 transactions | — | 13.3Kas of Jun 2025 | 52.5K | — | — |
| Myers C. DanielDirector · 5 transactions | — | 10.4Kas of Jun 2025 | 10.4K | — | — |
| Farid MarjanDirector · 5 transactions | — | 10.2Kas of Jun 2025 | 10.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +19.07M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.